Knight Therapeutics Inc. (TSE:GUD – Get Free Report) Senior Officer Amal Khouri sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of C$5.75, for a total value of C$28,750.00.
Amal Khouri also recently made the following trade(s):
- On Thursday, July 11th, Amal Khouri sold 10,000 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.70, for a total transaction of C$57,000.00.
- On Wednesday, July 3rd, Amal Khouri sold 10,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$5.72, for a total transaction of C$57,200.00.
- On Monday, June 10th, Amal Khouri sold 20,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$5.80, for a total transaction of C$116,022.00.
Knight Therapeutics Price Performance
Shares of GUD stock traded down C$0.05 during mid-day trading on Wednesday, reaching C$5.69. The company’s stock had a trading volume of 9,109 shares, compared to its average volume of 64,570. The company has a debt-to-equity ratio of 9.20, a quick ratio of 1.79 and a current ratio of 3.34. The firm’s 50-day moving average is C$5.66 and its two-hundred day moving average is C$5.64. Knight Therapeutics Inc. has a 1-year low of C$4.35 and a 1-year high of C$6.22. The company has a market cap of C$576.85 million, a P/E ratio of -35.88, a PEG ratio of -1,013.50 and a beta of 0.46.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on GUD
Knight Therapeutics Company Profile
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Recommended Stories
- Five stocks we like better than Knight Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- Canopy Growth Stock: Can It Sustain Recent Gains?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Serve Robotics Is Serving Up a Selling Opportunity
- Health Care Stocks Explained: Why You Might Want to Invest
- Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.